Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Fluoguide’s Q1 2026 report.</li><li>The quarter was marked by two consecutive FDA decisions that together define the near-term roadmap: authorisation to proceed with the first U.S. registration-directed Phase 2 trial in high-grade glioma (CT-006) and Fast Track Designation for FG001 in the same indication.</li><li>The remainder of the year is set to be an eventful period for the company, with upcoming study data, the start of a study, and a possible partnership agreement.</li></ul>

Redeye comments on Fluoguide’s Q1 2026 report.The quarter was marked by two consecutive FDA decisions that together define the near-term roadmap: authorisation to proceed with the first U.S. registration-directed Phase 2 trial in high-grade glioma (CT-006) and Fast Track Designation for FG001 in the same indication.The remainder of the year is set to be an eventful period for the company, with upcoming study data, the start of a study, and a possible partnership agreement.

FluoGuide (Q1 Review): Catalyst-Heavy Remainder of 2026